F2-isoprostanes as biomarkers of late-onset Alzheimer's disease

Thomas J. Montine, Joseph Quinn, Jeffrey Kaye, Jason D. Morrow

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a syndrome caused by a few uncommon mutations that lead to early-onset disease, occurs in adults with Down's syndrome, but is by far most commonly seen as a late-onset disease with multiple risk factors but no causative factors yet identified. Emerging data suggests a chronic disease model for AD with latency, prodrome, and dementia stages together lasting decades. Free radical damage to lipids in brain is one pathogenic process of AD that may be quantified with F2-isoprostanes (IsoPs). Whereas brain and cerebrospinal fluid (CSF) F2-IsoPs are reproducibly elevated in AD patients at both dementia and prodromal stages of disease, plasma and urine F2-IsoPs are not reproducibly increased in AD patients. CSF F2-IsoPs may be used to assist in diagnosis and aid in objective assessment of disease progression and response to therapeutics in patients with AD.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalJournal of Molecular Neuroscience
Volume33
Issue number1
DOIs
StatePublished - Sep 2007

Fingerprint

F2-Isoprostanes
Biomarkers
Alzheimer Disease
Cerebrospinal Fluid
Dementia
Cerebrospinal fluid
Prodromal Symptoms
Brain
Down Syndrome
Free Radicals
Disease Progression
Chronic Disease
Urine
Lipids
Mutation

Keywords

  • Alzheimer's disease
  • Dementia
  • F-Isoprostanes
  • Latency
  • Prodrome

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry
  • Genetics

Cite this

F2-isoprostanes as biomarkers of late-onset Alzheimer's disease. / Montine, Thomas J.; Quinn, Joseph; Kaye, Jeffrey; Morrow, Jason D.

In: Journal of Molecular Neuroscience, Vol. 33, No. 1, 09.2007, p. 114-119.

Research output: Contribution to journalArticle

@article{0c7eeeffd35a41ee9c4b1b6d47b19008,
title = "F2-isoprostanes as biomarkers of late-onset Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a syndrome caused by a few uncommon mutations that lead to early-onset disease, occurs in adults with Down's syndrome, but is by far most commonly seen as a late-onset disease with multiple risk factors but no causative factors yet identified. Emerging data suggests a chronic disease model for AD with latency, prodrome, and dementia stages together lasting decades. Free radical damage to lipids in brain is one pathogenic process of AD that may be quantified with F2-isoprostanes (IsoPs). Whereas brain and cerebrospinal fluid (CSF) F2-IsoPs are reproducibly elevated in AD patients at both dementia and prodromal stages of disease, plasma and urine F2-IsoPs are not reproducibly increased in AD patients. CSF F2-IsoPs may be used to assist in diagnosis and aid in objective assessment of disease progression and response to therapeutics in patients with AD.",
keywords = "Alzheimer's disease, Dementia, F-Isoprostanes, Latency, Prodrome",
author = "Montine, {Thomas J.} and Joseph Quinn and Jeffrey Kaye and Morrow, {Jason D.}",
year = "2007",
month = "9",
doi = "10.1007/s12031-007-0044-1",
language = "English (US)",
volume = "33",
pages = "114--119",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - F2-isoprostanes as biomarkers of late-onset Alzheimer's disease

AU - Montine, Thomas J.

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Morrow, Jason D.

PY - 2007/9

Y1 - 2007/9

N2 - Alzheimer's disease (AD) is a syndrome caused by a few uncommon mutations that lead to early-onset disease, occurs in adults with Down's syndrome, but is by far most commonly seen as a late-onset disease with multiple risk factors but no causative factors yet identified. Emerging data suggests a chronic disease model for AD with latency, prodrome, and dementia stages together lasting decades. Free radical damage to lipids in brain is one pathogenic process of AD that may be quantified with F2-isoprostanes (IsoPs). Whereas brain and cerebrospinal fluid (CSF) F2-IsoPs are reproducibly elevated in AD patients at both dementia and prodromal stages of disease, plasma and urine F2-IsoPs are not reproducibly increased in AD patients. CSF F2-IsoPs may be used to assist in diagnosis and aid in objective assessment of disease progression and response to therapeutics in patients with AD.

AB - Alzheimer's disease (AD) is a syndrome caused by a few uncommon mutations that lead to early-onset disease, occurs in adults with Down's syndrome, but is by far most commonly seen as a late-onset disease with multiple risk factors but no causative factors yet identified. Emerging data suggests a chronic disease model for AD with latency, prodrome, and dementia stages together lasting decades. Free radical damage to lipids in brain is one pathogenic process of AD that may be quantified with F2-isoprostanes (IsoPs). Whereas brain and cerebrospinal fluid (CSF) F2-IsoPs are reproducibly elevated in AD patients at both dementia and prodromal stages of disease, plasma and urine F2-IsoPs are not reproducibly increased in AD patients. CSF F2-IsoPs may be used to assist in diagnosis and aid in objective assessment of disease progression and response to therapeutics in patients with AD.

KW - Alzheimer's disease

KW - Dementia

KW - F-Isoprostanes

KW - Latency

KW - Prodrome

UR - http://www.scopus.com/inward/record.url?scp=35348817935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348817935&partnerID=8YFLogxK

U2 - 10.1007/s12031-007-0044-1

DO - 10.1007/s12031-007-0044-1

M3 - Article

VL - 33

SP - 114

EP - 119

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 1

ER -